Corvus co-founded Angel Pharma to develop its pipeline in greater China. Angel Pharma licensed the rights from Corvus to develop, manufacture and commercialize soquelitinib in greater China and is responsible for all expenses related to its development in China. "Atopic dermatitis affects patients worldwide, including a significant number in China where treatment with biologics and other systemic therapies is growing in use," said Richard A. Miller, M.D., co-founder, president and chief executive officer of ...

Core Insights - Corvus Pharmaceuticals announced new interim data from a Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis, which will be presented at the Society for Investigative Dermatology 2025 Annual Meeting [1][2] - The company will discuss this data during its first quarter 2025 business update conference call scheduled for May 8, 2025 [1][3] Presentation Details - The presentation titled "Selective Soquelitinib, a selective ITK inhibitor demonstrates activity in atopic dermatitis phase 1 clinical trial by a novel mechanism of action" will be delivered by Dr. Albert S. Chiou [2] - The poster presentation is set for May 8, 2025, from 4:30 – 6:00 pm PT, while the oral presentation will occur on May 10, 2025, from 9:50 – 10:00 am PT [2] Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on ITK inhibition as a novel immunotherapy approach for various cancers and immune diseases [4] - The lead product candidate, soquelitinib, is an investigational oral small molecule drug that selectively inhibits ITK, with other candidates in development for different cancer indications [4]